These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33992687)

  • 1. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.
    Winchester S; John S; Jabbar K; John I
    J Infect; 2021 Aug; 83(2):237-279. PubMed ID: 33992687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.
    Tandon M; Wu W; Moore K; Winchester S; Tu YP; Miller C; Kodgule R; Pendse A; Rangwala S; Joshi S;
    Lancet Reg Health Southeast Asia; 2022 Aug; 3():100036. PubMed ID: 35784831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
    J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.
    Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B
    Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.
    Chavda VP; Patel AB; Vora LK; Singla RK; Shah P; Uversky VN; Apostolopoulos V
    Curr Pharm Des; 2022; 28(46):3658-3670. PubMed ID: 36284382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial.
    Colado Simão AN; Perugini Stadtlober N; Stinghen Garcia Lonni AA; Venâncio LM; Lerner Trigo G; de Souza Cassela PLC; Mastellini Sanches Silva T; De Fátima Oliveira Hirth Ruiz M; Batisti Lozovoy MA; Tano ZN; da Fonseca Orcina B; Vieira Vilhena F; da Silva Santos PS
    Ger Med Sci; 2023; 21():Doc07. PubMed ID: 37426884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.
    Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E
    J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
    Klussmann JP; Grosheva M; Meiser P; Lehmann C; Nagy E; Szijártó V; Nagy G; Konrat R; Flegel M; Holzer F; Groß D; Steinmetz C; Scherer B; Gruell H; Schlotz M; Klein F; de Aragão PA; Morr H; Al Saleh H; Bilstein A; Russo B; Müller-Scholtz S; Acikel C; Sahin H; Werkhäuser N; Allekotte S; Mösges R
    Sci Rep; 2023 Apr; 13(1):6839. PubMed ID: 37100830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).
    Xu K; Chen Y; Yuan J; Yi P; Ding C; Wu W; Li Y; Ni Q; Zou R; Li X; Xu M; Zhang Y; Zhao H; Zhang X; Yu L; Su J; Lang G; Liu J; Wu X; Guo Y; Tao J; Shi D; Yu L; Cao Q; Ruan B; Liu L; Wang Z; Xu Y; Liu Y; Sheng J; Li L
    Clin Infect Dis; 2020 Jul; 71(15):799-806. PubMed ID: 32271376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.
    Friedland PL; Tucker S
    Laryngoscope; 2024 Mar; ():. PubMed ID: 38554057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal nitric oxide is decreased in acute mild COVID-19 and related to viral load.
    Tamminen PJ; Kerimov DM; Viskari H; Aittoniemi J; Syrjänen J; Lehtimäki L
    J Breath Res; 2022 Jul; 16(4):. PubMed ID: 35772381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19.
    Aref ZF; Bazeed SEES; Hassan MH; Hassan AS; Rashad A; Hassan RG; Abdelmaksoud AA
    Int J Nanomedicine; 2021; 16():4063-4072. PubMed ID: 34163159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the use of nasal and oral antiseptics during a global pandemic.
    Stathis C; Victoria N; Loomis K; Nguyen SA; Eggers M; Septimus E; Safdar N
    Future Microbiol; 2021 Jan; 16(2):119-130. PubMed ID: 33464122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal spray of an IgM-like ACE2 fusion protein HH-120 prevents SARS-CoV-2 infection: Two investigator-initiated postexposure prophylaxis trials.
    Song R; Chen X; Li B; Ni J; Zhou Y; Zhang H; Liang X; Zou L; Liu J; Yang F; Li G; Guo X; Liu Z; Mao F; Lei C; Sui J; Li W; Jin R
    J Med Virol; 2023 Dec; 95(12):e29275. PubMed ID: 38054556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.
    Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
    Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
    Front Immunol; 2020; 11():1936. PubMed ID: 32849650
    [No Abstract]   [Full Text] [Related]  

  • 18. Saying no to SARS-CoV-2: the potential of nitric oxide in the treatment of COVID-19 pneumonia.
    Zhang H; Zhang C; Hua W; Chen J
    Med Gas Res; 2024; 14(2):39-47. PubMed ID: 37929506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey.
    Shmuel K; Dalia M; Tair L; Yaakov N
    Expert Rev Anti Infect Ther; 2021 Oct; 19(10):1325-1330. PubMed ID: 33759682
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporine A micellar nasal spray characterization and antiviral action against SARS-CoV-2.
    Guareschi F; Del Favero E; Ricci C; Cantù L; Brandolini M; Sambri V; Nicoli S; Pescina S; D'Angelo D; Rossi I; Buttini F; Bettini R; Sonvico F
    Eur J Pharm Sci; 2024 Feb; 193():106673. PubMed ID: 38103657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.